里昂发表报告指,药明康德(02359.HK) 2025年第四季度业绩符合盈利预告。在人民币年内升值及地缘政治不确定性加剧的背景下,该行对公司2026年指引感到鼓舞,包括整体收入增长13-17%,持续经营业务收入增长18-22%。报告指,药明康德订单势头依然强劲,将2026-2027年净利润预测上调1-2%,并将H股/A股目标价分别由143.4港元/130.3元人民币,调整至144.4港元/...
Source Link里昂发表报告指,药明康德(02359.HK) 2025年第四季度业绩符合盈利预告。在人民币年内升值及地缘政治不确定性加剧的背景下,该行对公司2026年指引感到鼓舞,包括整体收入增长13-17%,持续经营业务收入增长18-22%。报告指,药明康德订单势头依然强劲,将2026-2027年净利润预测上调1-2%,并将H股/A股目标价分别由143.4港元/130.3元人民币,调整至144.4港元/...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.